Inventor · disambiguated record
Yongzhi Shu
Also filed as: SHU YONGZHI
4 granted patents·3 pending applications·4 citations·filing 2014–2022
60Inventor score
Top patents by PatentIndex Score
7 records- 0178US11155561B2Substituted glutarimides as Btk inhibitorsSHANGHAI MEIZER PHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 26, 2021·2 cites·13 claims
- 0277US11485726B2Compound for inhibiting and degrading tyrosine protein kinase ALKSHANGHAI MEIZER PHARMACEUTICALS CO LTD·Filed 2020·Granted Nov 1, 2022·2 cites·9 claims
- 0353US2021363148A1Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activitySHANGHAI MEIZER PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 0451US2025214960A1Compounds having activity of degrading gspt1 and application thereofSHANGHAI MEIZER PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0549US9650403B2Platinum (II) compound, preparation method therefor, and pharmaceutical composition and application thereofSHANGHAI INST PHARMACEUTICAL IND·Filed 2014·Granted May 16, 2017·0 cites·21 claims
- 0647US2024002389A1Compound for targeted degradation of btk and anti-tumour use thereofSHANGHAI MEIZER PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 0739US11236090B2Substituted glutarimides as CDK inhibitorsSHANGHAI MEIZER PHARMACEUTICALS CO LTD·Filed 2020·Granted Feb 1, 2022·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Yongzhi Shu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →